IRF2BPL

Across TCGA pan-cancer cohorts, IRF2BPL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IRF2BPL data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IRF2BPL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IRF2BPL expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where IRF2BPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.918	0.654	<.001	29	view →
HNSC	OS	Tertile	All	0.793	0.900	.014	22	view →
PDAC	DFS	Median	III,IV	0.182	0.495	.021	15	view →
CCRCC	DFS	Median	III,IV	0.701	0.439	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IRF2BPL–LSCC (OS)

Open the LSCC breakdown →